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Abstract
Background: Staphylococcus aureus is associated with human skin and soft tissue infections (SSTIs); however, the
involvement of virulence factors in different clinical presentations is unclear.
Methods: We analyzed methicillin-resistant S. aureus (MRSA) and methicillin-sensitive S. aureus (MSSA) strains from
Taiwan to determine correlations among the clinical characteristics of SSTIs, antimicrobial susceptibility and
virulence factors of S. aureus with specific genetic backgrounds.
Results: We identified 177 MRSA isolates and 130 MSSA isolates among the 307 SSTI-associated S. aureus isolates.
Hospital-acquired (HA)- and community-acquired (CA)-MRSA isolates accounted for 61.6 % and 38.4 % of the isolates,
respectively. Clinical presentations in SSTI patients differed significantly for the disease groups. Deep-seated MRSA
infections presented with higher amputation rate than MSSA infections. MRSA isolates were all susceptible to linezolid,
teicoplanin, and vancomycin, and >94 % of isolates were erythromycin- and clindamycin-resistant. Staphylococcal
cassette chromosome (SCCmec) types IV, V, and VII were the most frequent in the CA-MRSA group (n = 68); types
III, IV and V were the most frequent in the HA-MRSA group (n = 109). Panton-Valentine leukocidin (PVL) genes
were significantly more frequent in CA-MRSA strains (75.0 %) than in HA-MRSA (33.0 %) and MSSA (24.6 %) and
were found in 66.7 % (74/111) strains isolated from the abscess group. Exfoliatin A genes were more common in
catheter-related exit-site MSSA infections (37.5 %) compared with other MSSA disease groups (P < 0.05). Exfoliatin
B and superantigen exotoxin genes were uncommon in all SSTI disease types. Pulsotypes A (ST239), C, and D
(ST59) were the predominant MRSA genotypes in deep-seated infections.
Conclusions: If not treated appropriately, deep-seated MRSA-associated infections present with higher amputation rates
than deep-seated MSSA-associated infections. PVL-positive MRSA strains caused more frequently pus-forming lesions and
less bacteremia and invasive diseases. Methods for discriminating CA-MRSA from HA-MRSA strains are now unreliable due
to circulation of both ST 239 and ST 59 strains in the community and nosocomial settings. Initial antibiotic treatments
should consider MRSA for patients with SSTIs in areas where MRSA is prevalent.
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Background
Staphylococcus aureus is a major pathogen responsible
for skin and soft tissue infections (SSTIs) in humans.
The number of SSTI episodes with a culture-confirmed
pathogen increased from 11 % to 24 % between 1998
and 2009, while the incidence of methicillin-resistant S.
aureus (MRSA) increased from 5 % in 1998 to 42 % in
2005 before decreasing to 37 % in 2009 [1]. In the USA,
colonization by S. aureus is high among SSTI patients,
particularly that of USA300 MRSA [2]. In Taiwan, the
prevalence of MRSA in most of the major hospitals
ranged from 53 % to 83 % [3]; MRSA is a major patho-
gen related to SSTIs [4].
It is considered that community-acquired (CA)-MRSA
strains are more virulent than hospital-acquired (HA)-
MRSA because they possess specific virulence factors and
they spread more readily than CA-methicillin-sensitive S.
aureus (CA-MSSA) [5, 6]. Various extracellular proteins
produced by S. aureus have been reported to mediate dis-
eases with distinct cutaneous and systemic features. For
example, superantigen exotoxin (TSST-1) is associated
with staphylococcal toxic shock syndrome, exhibiting des-
quamative skin rash and multiple organ failure [7]. Exfo-
liatin A (ETA) and exfoliatin B (ETB) are associated with
staphylococcal scalded-skin syndrome with localized and
generalized blister formation [8]. Panton-Valentine leuko-
cidin (PVL) and γ-hemolysin (Hlg) target immune cells,
such as polymorphonuclear cells and macrophages, to
cause pus-forming SSTIs [9]. However, the actual correla-
tions between S. aureus virulence factors and the patho-
genesis of different SSTI clinical presentations are unclear.
The surgical timing and the choice of empiric antimi-
crobials when treating S. aureus-associated SSTI are still
controversial because of different clinical presentations
and regional variations in their prevalence [10]. In this
preliminary study, the clinical characteristics of SSTIs,
antimicrobial susceptibilities, and the virulence factors




This study was performed at the Chiayi Christian Hospital,
a 1000-bed teaching hospital in southern Taiwan, between
January 2008 and November 2008 and was approved by
the research ethics committee of the Chiayi Christian Hos-
pital (097032 and 101051). The medical records of patients
diagnosed with SSTI were reviewed, including demo-
graphic data, the type of infection, and underlying chronic
illnesses (e.g., diabetes mellitus, hypertension, chronic
liver disease, coronary artery disease, chronic renal
insufficiency, chronic obstructive pulmonary disease, or
malignancy). We categorized 307 cases of S. aureus
SSTIs on the basis of peculiarity and severity of their
clinical presentations into six distinct groups as follows:
deep-seated infection (necrotizing fasciitis, osteomye-
litis, pyomyositis, and septic arthritis), cutaneous infec-
tion (cellulitis, bullous impetigo, furuncle, carbuncle,
and staphylococcal scalded-skin syndrome), abscess
requiring surgical intervention, postpartum mastitis,
catheter-related (peritoneal catheter or intravascular cath-
eter) exit-site infection, or SSTI-related bacteremia. We
also documented the microbiological data, appropriate-
ness of empiric antibiotics, number of surgical interven-
tions and reconstructions, need for amputation, length of
hospital stay, and the in-hospital mortality rate.
Bacterial isolates
In total, 307 SSTI-associated S. aureus were identified
based on their characteristic colony morphology, Gram
staining, and the catalase reaction (Staphaurex Plus,
Remel, KS, USA). Blood cultures were processed using
a VITEK 2 GP system (BioMerieux Vitek, Hazelwood,
MO, USA) in the hospital laboratory. S. aureus was fur-
ther confirmed by polymerase chain reaction (PCR) to
detect the clfA, 16S rRNA, and nuc genes, as described
previously [11]. BCRC 10781 and BCRC 15211 were used
as the methicillin-susceptible and -resistant reference
strains, respectively. The HA-MRSA and CA-MRSA iso-
lates were defined as described previously [12].
Antimicrobial susceptibility testing
Antimicrobial susceptibility was tested using the disc dif-
fusion method according to the guidelines of the Clinical
and Laboratory Standards Institute [13]. We determined
the susceptibility to clindamycin, erythromycin, fusidic
acid, linezolid, oxacillin, penicillin, rifampicin, teicopla-
nin, tetracycline, trimethoprim-sulfamethoxazole, and
vancomycin (BBL, BD, USA). Isolates were considered to
be susceptible isolates when their zones of inhibition
conformed to the intermediate susceptibility category for
a given antibiotic.
PCR identification of staphylococcal cassette chromosome
(SCCmec) types and genes for virulence factors
SCCmec types I–IV were identified by multiplex PCR
amplification of the SCCmec region [14, 15]. If isolates
could not be assigned to types I–IV, they were grouped
into SCCmec types V or VII based on the PCR detection
of ccrC (ccr5) homologues [16–18]. Genes for virulence
factors, namely PVL, Hlg, TSST-1, ETA, and ETB, were
identified by simplex and multiplex PCR amplification
using primers, as described previously [19, 20].
Genetic analysis by pulsed field gel electrophoresis
(PFGE) and multilocus sequence typing (MLST)
The genotype of each isolate was identified by SmaI-
digested PFGE analysis, and the results were visually
Changchien et al. BMC Infectious Diseases  (2016) 16:276 Page 2 of 8
interpreted as previously described [21, 22]. The MLST
types of 16 CA- and HA-MRSA isolates were identified
using the method described by Enright [23] and by refer-
ence to MLST databases (http://saureus.mlst.net).
Statistical analysis
Statistical analyses were performed using SPSS 12.0 (SPSS
Inc, Chicago, IL, USA). The Student’s t-test (two-tailed)
was used to compare mean values. The clinical and cat-
egorical data for SSTI patients infected with MRSA or
MSSA were compared by ANOVA (Duncan’s test). P < 0.05
was considered statistically significant.
Results
Patient characteristics
Clinical S. aureus isolates were collected from 307 SSTI
patients, among whom 130 (42.3 %) patients were infected
by MSSA and 177 (57.7 %) by MRSA. CA-MRSA and
HA-MRSA infections accounted for 68 (38.4 %) and 109
(61.6 %) respectively. Abscess requiring surgical interven-
tion (36.2 %) and cutaneous infection (34.2 %) were the
most common clinical features of S. aureus-associated
SSTI, followed by deep-seated infection (16.9 %), SSTI-
related bacteremia (11.4 %), catheter-related exit-site in-
fection (8.1 %), and mastitis (5.2 %). MRSA was more
prevalent in all disease groups than MSSA. The most sig-
nificant predisposing factor was diabetes mellitus (33.6 %),
followed by chronic renal diseases (23.5 %) and chronic
liver diseases (9.7 %).
Univariate analyses of selected clinical characteristics of
SSTI showed significant differences in the clinical presen-
tations of various disease types, excluding the mortality
rate. For example, the deep-seated infection group had
higher comorbidity and amputation rates than did the
abscess group, and the SSTI-related bacteremia group had
the highest mean age and duration of hospitalization
(Tables 1 and 2). However, most of the clinical charac-
teristics of MRSA-associated SSTI were similar to those of
MSSA-associated SSTIs for each infection type (Table 3),
except MRSA-associated deep-seated infections presented
with a higher amputation rate than did MSSA-associated
ones (20.6 % vs. 0, P < 0.05).
Antimicrobial agents were generally used to treat
these SSTIs in both MRSA- and MSSA-infected pa-
tients (86.4 % vs. 78.5 %). Most patients (93 %) with
MSSA infections received an effective empiric anti-
microbial agent. However, 78.1 % of the patients with
MRSA infections received ineffective empiric antimicro-
bial therapy, where β-lactam antimicrobials were mostly
used. Vancomycin was initially prescribed to treat 6.2 % of
the MRSA infections and 7.7 % of the MSSA infections.
SCCmec typing and antimicrobial susceptibility testing
The SCCmec types of 177 MRSA isolates are shown in
Table 4. The mecA genes were identified in all (68/68)
CA-MRSA strains, 99.1 % (108/109) of HA-MRSA strains,
and 2.3 % (3/130) of MSSA strains. The major SCCmec
types were small-sized SCCmec types IV, V, and VII in
CA-MRSA strains, and SCCmec types III, IV, and V in
HA-MRSA strains. SCCmec III-carrying isolates were
more prevalent in patients with catheter-related exit-site
infections (35.3 %) and SSTI-related bacteremia (34.8 %)
than patients with mastitis (9.0 %) or abscesses (8.1 %) (P
< 0.05). SCCmec VII-carrying isolates were more prevalent
in patients with abscesses (27.4 %) than in those with
catheter-related exit-site infection (0) (P < 0.05) (Table 5).
The antibiotic resistance patterns differed significantly
among the various SCCmec types. The majority of the iso-
lates that contained SCCmec IV, V, or VII elements were
susceptible to trimethoprim-sulfamethoxazole (SXT) but
were resistant to β-lactams, erythromycin, and clindamy-
cin. SCCmec type II or III isolates were more resistant
to fusidic acid than SCCmec type IV, V, or VII isolates
(P < 0.05). All S. aureus isolates were susceptible to li-
nezolid, teicoplanin, and vancomycin. Most MSSA iso-
lates were susceptible to all antibiotics tested, excluding
penicillin. Over 94 % MRSA isolates were resistant to




infection (n = 34)
Cutaneous
infection (n = 54)







Mean age (years) 58.4ab 50.6bc 39.7cd 30.7d 68.3a 60.8ab <0.001
Mean comorbidities 2.2b (Range 0–5) 1.9b (Range 0–6) 0.9c (Range 0–5) 0.1c (Range 0–1) 3.4a (Range 0–7) 3.5a (Range 0–7) <0.001
Mean operative procedure 1.2a (Range 0–3) 0c (Range 0–1) 1.2a (Range 0–6) 0.1bc (Range 0–1) 0.5b (Range 0–2) 0.1bc (Range 0–2) <0.001
Reconstructive surgery (%) 4 (11.8)a 0 (0)b 1 (1.6)b 0 (0)b 0 (0)b 0 (0)b <0.01
Amputation (%) 7 (20.6)a 0 (0)b 2 (3.2)b 0 (0)b 3 (13.4)ab 0 (0)b <0.001
Mean hospitalization days 16.9ab 9.1b 9.6b 0.5c 19.2a 13.3ab <0.01
Mortality (%) 0 (0) 3 (5.6) 0 (0) 0 (0) 1 (4.3) 0 (0) 0.248
abValues in a row followed by different letters indicate significant difference between groups; P < 0.05
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erythromycin and clindamycin. Compared with CA-
MRSA isolates, HA-MRSA isolates were more resistant
to fusidic acid and SXT (Fig. 1).
Prevalence of PVL, Hlg, TSST-1, ETA, and ETB genes
The PVL gene was identified in 38.8 % S. aureus isolates
and was significantly more frequent in CA-MRSA strains
(75.0 %, 51/68) than in HA-MRSA (33.0 %, 36/109) and
MSSA strains (24.6 %, 32/130) (P < 0.01) (Table 4). Irre-
spective of the methicillin-resistance phenotype, PVL
genes were detected most frequently in abscesses, i.e.,
66.7 % (74/111), followed by mastitis, cutaneous infections,
deep-seated infections, bacteremia, and catheter-related
infections. Among all of the SSTI cases, only one ETB
gene was identified from a patient with staphylococcal
scalded-skin syndrome. Compared with other MSSA dis-
ease groups, ETA genes were more common in catheter-
related exit-site MSSA infections (37.5 %) (P < 0.05). All
the MRSA isolates possessed Hlg genes, which were
otherwise only present in 92.3 % of the MSSA isolates
(P < 0.01). The TSST-1 gene was seldom identified in
any disease type (Table 6).
PFGE analysis
PFGE analysis separated 32 MRSA isolates from deep-
seated infections into eight pulsotypes, among which pul-
sotypes A, C, and D accounted for 78.1 % of the isolates.
Associations between pulsotypes and SCCmec types were
determined for pulsotype A with SCCmec type II
I (100 %) and pulsotype C with SCCmec type IV (88.9 %).
Pulsotype D contained diverse SCCmec elements (types II,
III, V, VII, and nontypeable SCCmec elements), but
SCCmec type V was the major type (40 % of pulsotype
D). MLST analysis identified pulsotype A as ST239 and
pulsotype C as ST59.
Discussion
S. aureus-associated SSTIs exhibit diverse clinical pre-
sentations, mediated by various bacterial toxins and host
susceptibility to some extent. Localized cutaneous infec-
tions in healthy individuals may resolve spontaneously




infection (n = 18)
Cutaneous
infection (n = 51)







Mean age (years) 53.7ab 48.0ab 39.5bc 27.0c 59.9a 52.9ab <0.05
Mean comorbidities 2.3ab (Range 0–5) 1.5bc (Range 0–6) 0.8cd (Range 0–4) 0d (Range 0) 3.0a (Range 1–7) 3.1a (Range 0–7) <0.001
Mean operative
procedure
1.6a (Range 0–3) 0.02e (Range 0–1) 1.2ab (Range 1–3) 0.2de (Range 0–1) 0.6cd (Range 0–3) 0.9bc (Range 0–2) <0.01
Reconstructive
surgery (%)
4 (22.2)a 0 (0)b 2 (4.1)b 0 (0)b 0 (0)b 0 (0)b <0.05
Amputation (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) NA
Mean hospitalization
days
13.2ab 6.9b 7.7ab 4.0b 18.3a 8.4ab <0.05
Mortality (%) 0 (0) 1 (2.0) 1 (2.0) 0 (0) 0 (0) 0 (0) 0.974
abValues in a row followed by different letters indicate significant difference between groups; P < 0.05





































Mean age (years) 58.4 53.7 50.6 48.0 39.7 39.5 30.7 27.0 68.3 59.9 60.8 52.9 <0.001 <0.05
Mean comorbidities 2.2 2.3 1.9 1.5 0.9 0.8 0.1 0 3.4 3.0 3.5 3.1 <0.001 <0.001
Mean operative
procedure
1.2 1.6 0 0.02 1.2 1.2 0.1 0.2 0.5 0.6 0.1 0.9 <0.001 <0.01
Reconstructive
surgery (%)
4 (11.8) 4 (22.2) 0 (0) 0 (0) 1 (1.6) 2 (4.1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) <0.01 <0.05
Amputation (%) 7 (20.6)* 0 (0) 0 (0) 0 (0) 2 (3.2) 0 (0) 0 (0) 0 (0) 3 (13.4) 0 (0) 0 (0) 0 (0) <0.001 NA
Mean hospitalization
days
16.9 13.2 9.1 6.9 9.6 7.7 0.5 4.0 19.2 18.3 13.3 8.4 <0.01 <0.05
Mortality (%) 0 (0) 0 (0) 3 (5.6) 1 (2.0) 0 (0) 1 (2.0) 0 (0) 0 (0) 1 (4.3) 0 (0) 0 (0) 0 (0) 0.248 0.974
*Indicates a significant difference between the MRSA and MSSA groups; P < 0.05
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using topical antimicrobials. However, the majority of
abscess-forming lesions usually require surgical interven-
tion. Aggressive antimicrobial treatment of deep-seated in-
fections and SSTI-related bacteremia is crucial for survival.
Compared with MSSA infections, MRSA infections may
present with different clinical characteristics and outcomes
for deep-seated infections, bacteremia, catheter-related in-
fections, and mastitis [24–26]. It has been reported that
patients with MRSA bacteremia have a significantly higher
mortality rate (15–60 %) and longer hospitalization dur-
ation compared with those with MSSA bacteremia [27]. By
contrast, Miller et al. reported that most clinical character-
istics of MRSA-associated SSTI could not be used as
markers to distinguish MSSA-infected patients [28]. Our
results indicate that deep-seated MRSA infections pre-
sented with a higher amputation rate than MSSA infections
(20.6 % vs. 0 %) (Table 3). It should be noted that most pa-
tients (78.1 %) with MRSA infections received ineffective
empiric antimicrobial therapy. Thus, the correlation be-
tween diverse clinical outcomes and inappropriate empiric
therapy for severe infections requires further study.
Catheter-related exit-site infection is a peculiar noso-
comial infection, which is usually associated with bac-
terial colonization and biofilm formation in SSTIs, and
has been reported as the most common source of S.
aureus bacteremia, with equal proportions of MSSA
and MRSA infection [29]. Here, patients with catheter-
related exit-site MRSA infections were more prevalent
and had more concurrent bacteremia (64.7 % vs. 0)
compared with MSSA infections, suggesting a greater
prevalence of MRSA in our hospital.
In general, S. aureus, β-hemolytic streptococcus, Escheri-
chia coli, and Bacteroides spp. have been isolated from
patients with postpartum mastitis. Among the mastitis-
associated MRSA isolates obtained in this investigation,
10/11 (90.9 %) were classified as HA-MRSA strains, but
their antimicrobial resistance patterns and PCR results in-
dicated that most isolates possessed the characteristics of
CA-MRSA strains.
According to the isolates analyzed by PFGE, the pre-
dominant MRSA genotypes were pulsotypes A, C, and D.
Pulsotype A isolates related to ST 239 are the major HA-
MRSA clones in Taiwan [30], whereas pulsotype C and D
isolates related to ST 59 are the prevalent clones of CA-
MRSA in Taiwan [3, 31]. However, we identified both ST
239 and ST 59 strains from CA and HA-SSTI patients,
thereby implying that both strains are circulating con-
comitantly in community and nosocomial settings.
It was notable that there was a significant association be-
tween PVL and MRSA, particularly in cutaneous abscess
compared with bacteremia and invasive illnesses. These
findings suggest that PVL-positive strains have a higher
tendency to develop pus-forming lesions that often require
surgical drainages. PVL-positive isolates were significantly
more prevalent among the CA-MRSA strains compared
with MSSA strains, as described previously [32], thereby
reflecting the consequences of the widespread use of β-
Table 4 Differences in prevalence of SCCmec types and virulence




CA-MRSA HA-MRSA MSSA P-value
(n = 68) (n = 109) (n = 130)
SCCmec
Type II 1 (1.4 %)c 4 (3.6 %)b 0 (0) 0.393
Type III 4 (5.9 %)c 27 (24.8 %)a 0 (0) <0.01
Type IV 20 (29.4 %)a 25 (22.9 %)a 0 (0) 0.339
Type V 21 (30.9 %)a 29 (26.6 %)a 0 (0) 0.541
Type VII 15 (22.1 %)ab 14 (12.8 %)b 0 (0) 0.108
Nontypeable 7 (10.3 %)bc,y 10 (9.2 %)b,y 130 (100 %)x <0.01
mecA 68 (100 %)a 108 (99.1 %)a 3 (2.3 %)b <0.01
Virulence factors
PVL 51 (75.0 %)x 36 (33.0 %)y 32 (24.6 %)y <0.01
Hlg 68 (100 %)x 109 (100 %)x 120 (92.3 %)y <0.01
TSST-1 4 (5.8 %) 4 (3.7 %) 7 (4.6 %) 0.725
ETA 14 (22.1 %)y 35 (29.6 %)x 23 (19.0 %)y <0.01
ETB 1 (1.4 %) 0 (0) 0 (0) 0.09
abDifferent letters in the same column indicate significant differences between
groups; P < 0.05
xyDifferent letters in the same row indicate significant differences between
groups; P < 0.05
Table 5 Differences in the prevalence of SCCmec types and virulence factors of MRSA among disease groups
SCCmec type Deep-seated
infection (n = 34)
Cutaneous
infection (n = 54)







Type II 2 (5.9 %) 2 (3.7 %) 1 (1.6 %) 0 (0) 0 (0) 0 (0) 0.608
Type III 9 (26.5 %)ab 10 (18.5 %)ab 5 (8.1 %)b 1 (9.0 %)b 8 (34.8 %)a 6 (35.3 %)a <0.05
Type IV 9 (26.5 %) 14 (25.9 %) 14 (22.6 %) 4 (36.4 %) 6 (26.1 %) 4 (23.5 %) 0.936
Type V 7 (20.5 %) 17 (31.5 %) 15 (24.2 %) 5 (45.5 %) 4 (17.4 %) 6 (35.3 %) 0.294
Type VII 4 (11.8 %)ab 8 (14.8 %)ab 17 (27.4 %)a 1 (9.0 %)ab 3 (13.0 %)ab 0 (0)b <0.05
Non-typeable 3 (8.8 %) 3 (5.0 %) 10 (16.1 %) 0 (0) 2 (8.7 %) 1 (5.9 %) 0.101
abValues in a row followed by different letters indicate significant differences between groups; P < 0.05
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lactam antibiotics, leading to the selection of a few re-
stricted PVL-positive MRSA strains. Furthermore, PVL
genes were identified in both CA- and HA-MRSA strains
that possessed SCCmec type III, although SCCmec type IV
isolates were dominant in both the CA- and HA-MRSA
groups (Table 4). Our results suggest that the SCCmec
types and the presence of PVL genes are not useful mo-
lecular markers for distinguishing between CA- and HA-
MRSA strains.
TSST-1, ETA, and ETB are reportedly the major viru-
lence factors associated with some peculiar skin and sys-
temic syndromes in clinical settings. The low carriage
rate of these genes in S. aureus isolates from SSTI pa-
tients could explain the low incidence of staphylococcal
toxic shock syndrome and staphylococcal scalded-skin
syndrome in the present study. Diverse skin and sys-
temic presentations of various disease types of SSTI may
be correlated with other exotoxin genes or combinations
of virulence factors. The mecA gene was not found in an
MRSA isolate in this study, which could be related to di-
verse resistance mechanisms, e.g., the production of β-
lactamase or other unidentified factors that may contribute
to resistance in MRSA [33]. Furthermore, three MSSA iso-
lates that possessed the mecA gene may have been derived
from a mecA-positive MRSA strain subpopulation with a
heterogeneous resistance phenotype that cannot be de-
tected by traditional susceptibility testing [34].
The treatment of SSTIs involves topical agents, surgi-
cal intervention, or oral or parenteral antimicrobial ther-
apy. Recent reports and the present study demonstrate
the high impact of MRSA in SSTIs [35]. Uncomplicated
skin abscesses are curable by surgical drainage alone; an-
timicrobials are not necessary according to the current
guidelines. In areas with a high prevalence of MRSA in-
fections, empiric antimicrobial treatment should con-
sider the possibility of MRSA infection in complicated
SSTIs and immunocompromised individuals. CA-MRSA
strains with type IV SCCmec elements are more suscep-
tible to a variety of non-β-lactam antimicrobials than are
HA-MRSA strains [36]; antimicrobial susceptibility pat-
terns have been used to discriminate CA-MRSA and
HA-MRSA strains. However, this approach is now unre-
liable because CA-MRSA may also acquire resistance to
non-β-lactam antibiotics [37]. Clindamycin has been
Fig. 1 Antimicrobial susceptibility of CA-MRSA, HA-MRSA, and MSSA. Different letters (a and b) indicate significant differences between
groups; P < 0.05
Table 6 Differences in virulence factors between MRSA and MSSA among disease groups
Virulence
factor


























PVL 7 (20.6 %) 1 (5.6 %) 27 (50.0 %)* 4 (7.8 %) 49 (79.0 %) 25 (51.0 %) 5 (45.5 %) 2 (40.0 %) 3 (13.0 %) 0 (0) 1 (5.9 %) 0 (0)
Hlg 34 (100 %) 17 (94.4 %) 54 (100 %) 47 (92.2 %) 62 (100 %) 46 (93.9 %) 11 (100 %) 4 (80.0 %) 23 (100 %) 12 (100 %) 17 (100 %) 7 (87.5 %)
TSST-1 4 (11.8 %) 0 (0) 2 (3.7 %) 2 (3.9 %) 2 (3.2 %) 5 (10.2 %) 0 (0) 0 (0) 1 (4.3 %) 1 (8.3 %) 0 (0) 1 (12.5 %)
ETA 7 (20.6 %) 4 (22.2 %) 15 (27.8 %) 12 (23.5 %) 18 (29.6 %) 2 (4.1 %) 3 (27.3 %) 1 (20.0 %) 5 (21.7 %) 3 (25.0 %) 5 (29.4 %) 3 (37.5 %)
ETB 0 (0) 0 (0) 1 (1.9 %) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
*Indicates a significant difference between MRSA and MSSA groups; P < 0.05
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used as an option for staphylococcal SSTIs due to its good
distribution in skin and wound exudates [38]. However,
we found that erythromycin and clindamycin resistance
were much more frequent (over 94 %) in both CA- and
HA-MRSA isolates than those reported recently from dif-
ferent countries [39]. The treatment guidelines for MRSA
infections should be adjusted according to the currently
defined efficacy of non-β-lactam antimicrobials. For com-
plicated SSTIs, the treatment of patients with appropriate
initial antimicrobials is associated with a statistically sig-
nificant impact on the cure rate [40]. According to the
susceptibility tests in the present study, SXT appears to be
an appropriate empiric oral antimicrobial for treating CA-
MRSA infections, whereas fusidic acid is more suitable for
treating both CA- and HA-MRSA infections (Fig. 1).
Vancomycin is warranted only for empiric use when treat-
ing deep-seated, life-threatening MRSA infections.
Conclusions
MRSA is an important emerging pathogen in SSTIs. Most
of the clinical characteristics of MRSA-associated SSTIs
are similar to those of MSSA-associated SSTIs, except for
the higher amputation rate in deep-seated MRSA infec-
tions. We found that PVL-positive strains had a higher ten-
dency to cause pus-forming lesions, whereas they were
rarely associated with bacteremia and invasive diseases.
ETB and TSST-1 genes were identified only rarely in vari-
ous SSTI disease types. The previously employed criteria
and antimicrobial susceptibility patterns for discriminating
CA- and HA-MRSA strains are now unreliable because
both ST 239 (major clone of HA-MRSA) and ST 59 (major
clone of CA-MRSA) strains are circulating concomitantly
in community and nosocomial settings in Taiwan. Early
surgical drainage of pus-forming lesions and appropriate
antimicrobials for invasive infections are mandatory for
SSTI treatment. If indicated, the initial empiric antimicro-
bial treatment should consider MRSA for patients with
SSTIs in areas where MRSA is prevalent.
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